Anti-Inflammatory Effects of Lysozyme Against HMGB1 in Human Endothelial Cells and in Mice

Overview

Journal Inflammation

Specialties Allergy & Immunology
Pathology

Date 2015 Apr 23

PMID 25899805

Citations 12

Authors

Wonhwa Lee

Sae-Kwang Ku

Dong Hee Na

Jong-Sup Bae

Affiliations

Soon will be listed here.

Abstract

High mobility group box 1 (HMGB1) was recently shown to be an important extracellular mediator of severe vascular inflammatory disease, sepsis. Lysozyme protects us from the ever-present danger of bacterial infection and binds to bacterial lipopolysaccharide (LPS) with a high affinity. Here, we show, for the first time, the anti-septic effects of lysozyme in HMGB1-mediated inflammatory responses in vitro and in vivo. The data showed that lysozyme posttreatment suppressed LPS-mediated release of HMGB1 and HMGB1-mediated cytoskeletal rearrangement. Lysozyme also inhibited HMGB1-mediated hyperpermeability and leukocyte migration in human endothelial cells. In addition, lysozyme inhibited the HMGB1-mediated activation of Akt, nuclear factor-κB (NF-κB), extracellular regulated kinases (ERK) 1/2 and production of interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), and chemoattractant protein-1 (MCP-1) in HUVECs. Furthermore, lysozyme reduced the cecal ligation and puncture (CLP)-induced release of HMGB1, migration of leukocytes, septic mortality, and pulmonary damage in mice. Collectively, these results suggest lysozyme as a candidate therapeutic agent for the treatment of vascular inflammatory diseases via inhibition of the HMGB1 signaling pathway.

Citing Articles

Spatial transcriptomics reveals prognostically LYZ fibroblasts and colocalization with FN1 macrophages in diffuse large B-cell lymphoma.

Dai L, Lou N, Huang L, Li L, Tang L, Shi Y Cancer Immunol Immunother. 2025; 74(4):123.

PMID: 39998673 PMC: 11861843. DOI: 10.1007/s00262-025-03968-7.

Polystyrene Nanoplastics Elicit Multiple Responses in Immune Cells of the (, 1826).

Shi H, Wang Y, Li X, Wang X, Qi Y, Hu S Toxics. 2025; 13(1).

PMID: 39853018 PMC: 11769107. DOI: 10.3390/toxics13010018.

Generation of Anti-Mastitis Gene-Edited Dairy Goats with Enhancing Lysozyme Expression by Inflammatory Regulatory Sequence using ISDra2-TnpB System.

Feng R, Zhao J, Zhang Q, Zhu Z, Zhang J, Liu C Adv Sci (Weinh). 2024; 11(38):e2404408.

PMID: 39099401 PMC: 11481229. DOI: 10.1002/advs.202404408.

Lysozyme promotes renal fibrosis through the JAK/STAT3 signal pathway in diabetic nephropathy.

Ren Y, Yu M, Zheng D, He W, Jin J Arch Med Sci. 2024; 20(1):233-247.

PMID: 38414445 PMC: 10895955. DOI: 10.5114/aoms/170160.

Heat-Denatured Lysozyme is a Novel Potential Non-alcoholic Disinfectant Against Respiratory Virus.

Huang S, Wu Z, Zhou B, Jiang X, Lavillette D, Fan G Food Environ Virol. 2023; 15(3):212-223.

PMID: 37155116 PMC: 10166042. DOI: 10.1007/s12560-023-09556-1.

References

Lee W, Yoo H, Ku S, Kim J, Bae J . Anticoagulant activities of piperlonguminine in vitro and in vivo. BMB Rep. 2013; 46(10):484-9. PMC: 4133832. DOI: 10.5483/bmbrep.2013.46.10.028. View

Schnittler H, Schneider S, Raifer H, Luo F, Dieterich P, Just I . Role of actin filaments in endothelial cell-cell adhesion and membrane stability under fluid shear stress. Pflugers Arch. 2001; 442(5):675-87. DOI: 10.1007/s004240100589. View

Rose B, Force T, Wang Y . Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010; 90(4):1507-46. PMC: 3808831. DOI: 10.1152/physrev.00054.2009. View

Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H . Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol. 2008; 104(1):42-9. DOI: 10.1007/s00395-008-0738-8. View

Takada K, Ohno N, Yadomae T . Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo. Infect Immun. 1994; 62(4):1171-5. PMC: 186250. DOI: 10.1128/iai.62.4.1171-1175.1994. View

Andersson U, Wang H, Palmblad K, Aveberger A, Bloom O, Erlandsson-Harris H . High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000; 192(4):565-70. PMC: 2193240. DOI: 10.1084/jem.192.4.565. View

Hansson G, Libby P . The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6(7):508-19. DOI: 10.1038/nri1882. View

Ramachandran G . Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence. 2013; 5(1):213-8. PMC: 3916377. DOI: 10.4161/viru.27024. View

Murakami S, Nagai J, Fujii K, Yumoto R, Takano M . Influences of dosage regimen and co-administration of low-molecular weight proteins and basic peptides on renal accumulation of arbekacin in mice. J Antimicrob Chemother. 2008; 61(3):658-64. DOI: 10.1093/jac/dkm512. View

10.

Kelly J, Sielecki A, Sykes B, James M, Phillips D . X-ray crystallography of the binding of the bacterial cell wall trisaccharide NAM-NAG-NAM to lysozyme. Nature. 1979; 282(5741):875-8. DOI: 10.1038/282875a0. View

11.

Rittirsch D, Huber-Lang M, Flierl M, Ward P . Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc. 2009; 4(1):31-6. PMC: 2754226. DOI: 10.1038/nprot.2008.214. View

12.

Diehl K, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D . A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol. 2001; 21(1):15-23. DOI: 10.1002/jat.727. View

13.

Sama A, DAmore J, Ward M, Chen G, Wang H . Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department. Acad Emerg Med. 2004; 11(8):867-73. DOI: 10.1197/j.aem.2004.03.011. View

14.

Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris H . Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A. 2003; 101(1):296-301. PMC: 314179. DOI: 10.1073/pnas.2434651100. View

15.

Wichterman K, Baue A, Chaudry I . Sepsis and septic shock--a review of laboratory models and a proposal. J Surg Res. 1980; 29(2):189-201. DOI: 10.1016/0022-4804(80)90037-2. View

16.

Lee W, Kim T, Ku S, Min K, Lee H, Kwon T . Barrier protective effects of withaferin A in HMGB1-induced inflammatory responses in both cellular and animal models. Toxicol Appl Pharmacol. 2012; 262(1):91-8. DOI: 10.1016/j.taap.2012.04.025. View

17.

Bae J . Role of high mobility group box 1 in inflammatory disease: focus on sepsis. Arch Pharm Res. 2012; 35(9):1511-23. DOI: 10.1007/s12272-012-0901-5. View

18.

Ku S, Bae J . Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and FIIa/FXa. Arch Pharm Res. 2014; 37(11):1454-63. DOI: 10.1007/s12272-014-0403-8. View

19.

Wang H, Yang H, Czura C, Sama A, Tracey K . HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med. 2001; 164(10 Pt 1):1768-73. DOI: 10.1164/ajrccm.164.10.2106117. View

20.

Tracey K, Fong Y, Hesse D, Manogue K, Lee A, Kuo G . Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987; 330(6149):662-4. DOI: 10.1038/330662a0. View